Ocedurenone

Summary

Ocedurenone (CHEMBL5314961) is a phase-3 clinical-stage small molecule targeting NR3C2; indicated across 3 conditions including chronic kidney disease and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (NR3C2)
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 504 Da · C28H30ClN5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314961
Name	Ocedurenone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	75593324
Molecular formula	C28H30ClN5O2
Molecular weight	504
InChIKey	UXHQLGLGLZKHTC-CUNXSJBXSA-N

SMILES: C1CCC(C1)[C@H]2[C@H]3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=N4)C(=O)N6CCC(CC6)O

IUPAC name: 4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile

Also known as: Kbp-5074, KBP5074, Ocedurenone, OCEDURENONE

Patent coverage: 7 distinct patent families (24 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 22 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C2	Mineralocorticoid receptor	Antagonist	8.57	0%	P08235

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): NR3C2.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Cellular responses to stress	1	NR3C2
SUMOylation	1	NR3C2
SUMO E3 ligases SUMOylate target proteins	1	NR3C2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	1	NR3C2
Nuclear Receptor transcription pathway	1	NR3C2
Metabolism of proteins	1	NR3C2
SUMOylation of intracellular receptors	1	NR3C2
Post-translational protein modification	1	NR3C2
Cellular responses to stimuli	1	NR3C2

Dominant GO biological processes

GO term	Targets
regulation of transcription by RNA polymerase II	1
signal transduction	1
nuclear receptor-mediated steroid hormone signaling pathway	1
positive regulation of non-canonical NF-kappaB signal transduction	1
regulation of DNA-templated transcription	1
cellular response to hormone stimulus	1
response to lipid	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0003884
liver disorder	1	MONDO:0005154	EFO:0001421
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04968184	PHASE3	TERMINATED	Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
NCT02228733	PHASE1	COMPLETED	Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074
NCT02653014	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
NCT02837237	PHASE1	COMPLETED	Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
NCT03340753	PHASE1	COMPLETED	Bioavailability of KBP-5074 Tablet vs Capsule Formulations
NCT04534699	PHASE1	COMPLETED	Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
NCT04606537	PHASE1	COMPLETED	Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
NCT04634812	PHASE1	COMPLETED	Mass Balance Study of KBP-5074 in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

26 molecules share ≥1 primary target. Top 26 by shared-target count:

Molecule	Source	Status	Shared targets
EPLERENONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C2
BUDESONIDE	ChEMBL	Phase 4 (approved)	NR3C2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C2
FINERENONE	ChEMBL	Phase 4 (approved)	NR3C2
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C2
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C2
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C2
HYDROCORTISONE BUTYRATE	ChEMBL	Phase 4 (approved)	NR3C2
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	NR3C2
PREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C2
PROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C2
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	NR3C2
ASOPRISNIL	ChEMBL	Phase 3	NR3C2
BALCINRENONE	ChEMBL	Phase 3	NR3C2
CORTICOSTERONE	ChEMBL	Phase 3	NR3C2
ALDOSTERONE	ChEMBL	Phase 2	NR3C2
LY2623091	ChEMBL	Phase 2	NR3C2
METRIBOLONE	ChEMBL	Phase 2	NR3C2
MT-3995	ChEMBL	Phase 2	NR3C2
ONAPRISTONE	ChEMBL	Phase 2	NR3C2
STANOLONE	ChEMBL	Phase 2	NR3C2
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	NR3C2
Enzalutamide	PubChem	Approved	NR3C2
Fludrocortisone	PubChem	Approved	NR3C2
ursodiol	PubChem	Approved	NR3C2